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Abstract:  Actinomycetes are prolific producers of pharmacologically important 
compounds accounting for about 70% of the naturally derived antibiotics that are currently 
in clinical use. In this study, we report on the isolation of Streptomyces sp. strains from 
Mediterranean sponges, on their secondary metabolite production and on their screening 
for anti-infective activities. Bioassay-guided isolation and purification yielded three 
previously known compounds namely, cyclic depsipeptide valinomycin, indolocarbazole 
alkaloid staurosporine and butenolide. This is the first report of the isolation of 
valinomycin from a marine source. These compounds exhibited novel anti-parasitic 
activities specifically against Leishmania major (valinomycin IC50 < 0.11 µM; 
staurosporine IC50 5.30 µM) and Trypanosoma brucei brucei (valinomycin   
IC50 0.0032 µM; staurosporine IC50 0.022 µM; butenolide IC50 31.77 µM). These results 
underscore the potential of marine actinomycetes to produce bioactive compounds as well 
as the re-evaluation of previously known compounds for novel anti-infective activities. 
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1. Introduction 
The class Actinobacteria, specifically bacteria belonging to the order Actinomycetales, are common 
soil inhabitants that have the unprecedented ability to produce a wide range of secondary metabolites. 
Among the more than 140 described actinomycete genera, only a few are responsible for the majority 
of over 20,000 microbial natural products identified so far. In particular, the genus Streptomyces 
accounts for about 80% of the actinomycete natural products reported to date [1,2]. Given the 
unparalleled potential of actinomycetes and specifically streptomycetes in this regard, significant effort 
has been directed towards the isolation of these bacteria from various sources for drug screening 
programs. The majority of the actinomycetes were previously isolated from terrestrial soils and from 
marine sediments [3–5] and quite recently also from marine sponges [6–10] and cone snails [11]. The 
discovery of numerous marine actinomycete taxa and their bioactive secondary metabolites dispel the 
notion that actinomycetes are merely dormant spores that have been washed off from the   
shores [1,3,12,13].  
The major goal of our research is to discover novel anti-infective agents such as those against the 
parasites Leishmania major and Trypanosoma brucei that cause leishmaniasis and African sleeping 
sickness, respectively. These parasites currently affect around 12 million people living in tropical and 
subtropical areas [14]. The alarming death rate caused by these parasites and the emergence of 
antibiotic resistance underline the need for new and effective drugs. Our research program focuses on 
the discovery of anti-infective agents from marine sponges and their associated microorganisms. In the 
course of our study, we have taxonomically described two new actinomycete species [15,16] isolated 
from marine sponges as well as novel compounds [17]. During our screening efforts for bioactive 
natural products from marine sponge-associated actinomycetes, we have encountered some previously 
known compounds but with yet unprecedented biological activities. We report here the isolation and 
characterization of these compounds from actinomycetes associated with Mediterranean sponges with 
novel anti-parasitic activities. 
2. Results and Discussion 
Actinomycetes associated with the following sponges: Aplysina aerophoba, Axinella polypoides, 
Tedania sp. and Tethya sp. collected by SCUBA diving offshore Rovinj, Croatia (45°05′N, 13°38′E) in 
May 2006 were cultivated as described previously [15,16,18]. 16S rRNA gene sequencing revealed the 
affiliation of four strains, namely isolate 11 (GU214750), isolate 34 (GU214751), isolate 22 
(GU214752) and isolate TO3 (GU214749) to the genus Streptomyces (Figure 1). They exhibited   
99.7–99.9% sequence similarities to validly described species of the genus Streptomyces.  
The strains 22 and 34 collected from two different sponge species, Axinella polypoides and 
Aplysina aerophoba, respectively exhibited 99.9% 16S rRNA gene sequence similarities, with only 
one nucleotide difference. This suggests that these isolates are most probably the same strain and their 
isolation from different hosts indicates that these bacteria could be transient organisms coming from 
the surrounding seawater that were merely present within the sponge during collection.  Mar. Drugs 2010, 8  375
 
Figure 1. Neighbor-joining tree of the strains and representative species of the genus 
Streptomyces based on nearly complete 16S rRNA gene sequences. Numbers at the nodes 
indicate the levels of bootstrap support based on 1000 resampled data sets. Only values 
greater than 50% are shown. The arrow points to the outgroup consisting of six species 
belonging to Enterobacteriaceae  and  Pasteurellaceae.  The scale bar indicates 0.01 
substitution per nucleotide position. 
 
 
The strains 11, 22, 34 and T03 were each grown on 100 M1 [4] agar plates and incubated at 30 °C 
for seven days. Mycelial mass together with the agar were cut into small pieces and macerated 
overnight with 200 mL of ethyl acetate. The resulting solution was filtered using Whatman filter paper 
and the same maceration step with ethyl acetate was repeated. Both filtrates were combined and 
subsequently dried by rotary evaporation. The crude extracts were subjected to pre-fractionation with 
Diaion HP-20ss resin (Mitsubishi Chemical Corporation, Japan) using a gradient of water/isopropanol 
(100%, 75%:25%, 50%:50%, 25%:75%) followed by 100% MeOH. The fractions were subsequently 
purified by RP-HPLC (Agilent 1100, Agilent Technologies, USA). High resolution ESIMS analyses 
were performed on a Micromass Q-Tof micro mass spectrometer. NMR spectra were obtained on 
Varian INOVA 500 (
1H 500 MHz, 
13C 125 MHz) and Varian INOVA 600 (
1H 600 MHz, 
13C 150 MHz) 
NMR spectrometers with a 3 mm Nalorac MDBG probe and a 5 mm cold probe, respectively.  
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Figure 2. Compounds isolated from Streptomyces sp. strains. 
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High-resolution mass spectrometry of the purified compound both from Streptomyces sp. strains 22 
and 34 established a molecular formula of C54H90N6NaO18 (m/z 1133.6385 for [M + Na]
+, calculated 
1133.6394) [19]. A combination of NMR and MS-MS fragmentation suggested the presence of one  
α-hydroxyisovaleryl unit (Hiv), a lactoyl group (Lac), and two valines (Val), thus confirming the 
identity of the compound as valinomycin (Figure 2) (see Supplementary Information for NMR data). 
The isolation of the same compound from these strains is not surprising since both exhibited very high 
16S rRNA gene sequence similarities. This cyclodepsipeptide has been recovered from various   
soil-derived actinomycetes, Streptomyces fulvissimus, Streptomyces roseochromogenes and 
Streptomyces griseus var. flexipartum [20]. To date, this is the first report of valinomycin isolated from 
a marine organism. This cyclic depsipeptide consists of polar groups oriented toward the central 
cavity, whereas the rest of the molecule is relatively nonpolar thus behaving like an ionophore that 
modulates transport of ions such as potassium across biological membranes. In this study, valinomycin 
exhibited significant inhibitory activities against the parasites Leishmania major (IC50 < 0.11 µM) and 
Trypanosoma brucei brucei (IC50 0.0032 µM) [21,22]. Previous studies have shown other biological 
activities of valinomycin in insecticidal, nematocidal and antifungal assays [23]. 
Table 1. Anti-parasitic activities of the compounds (IC50, μM). 
 
Compound 
Leishmania 
major 
Trypanosoma brucei 
brucei (48 h) 
Trypanosoma brucei 
brucei (72 h) 
valinomycin <0.11  0.0032  0.0036 
staurosporine 5.30  0.022  0.035 
butenolide >100  31.77  33.08 
 
 
 Mar. Drugs 2010, 8  377
The compound staurosporine (Figure 2) was isolated from Streptomyces sp. strain 11 with a 
molecular formula of C11H18N2NaO2 (m/z 233.1262 for [M + Na]
+, calculated 233.1266) [24]. The 
structure was confirmed by comparison of NMR analysis (see Supplementary Information) with 
published spectral data of the compound [25]. This indolocarbazole alkaloid was previously isolated 
from various terrestrial Streptomyces sp. strains. Interestingly, staurosporine and its derivatives have 
also been isolated from the marine ascidian Eudistoma toealensis and its predatory flatworm 
Pseudoceros sp. [26]. Furthermore, staurosporine and its derivatives have aroused considerable interest 
as these compounds exhibit strong inhibitory activities against protein kinase C as well as inhibition of 
platelet aggregation, blocking of growth phases in cancer cells and reversal of multidrug resistance [27]. 
In this study, stauroporine exhibited significant anti-parasitic activity against Leishmania major  
(IC50 5.30 µM) and Trypanosoma brucei brucei (IC50 0.022 µM) which has not been previously 
reported in literature. 
The third compound, butenolide (Figure 2), was isolated from Streptomyces sp. strain T03 with a 
molecular formula of C13H22O3Na (m/z 249.1447 for [M + Na]
+, calculated 249.1467) exhibiting 
identical spectral data with published literature [28] (see Supplementary Information). This lactone-
containing metabolite has also been previously isolated from a marine sediment-derived   
Streptomyces sp. strain M027750 [28]. Butenolides are a family of α,β-unsaturated lactones commonly 
produced by fungi, bacteria and gorgonians (colonial soft corals). Their saturated analogs act as 
signaling substances in bacteria, enhance spore formation of Streptomyces  sp. as well as induce 
metabolite formation [29]. In this study, butenolide was found to exhibit anti-Trypanosoma activity  
(IC50 0.022 µM). 
The compounds valinomycin and staurosporine were found to exhibit general cytotoxicity against 
293T kidney epithelial cells (valinomycin IC50 11.24 µM; staurosporine IC50 1.30 µM) and J774.1 
macrophages (valinomycin IC50 < 0.10 µM; staurosporine IC50 < 0.13 µM) while butenolide was not 
found to exhibit cytotoxicity against these cell lines [30]. Nevertheless, these compounds have been 
shown to exhibit significant anti-parasitic activities (Table 1) which has not been previously reported. 
Structure modification of these compounds with the aim to decrease cytotoxicity is therefore a 
worthwhile endeavour. These results highlight the potential of actinomycetes associated with marine 
sponges to produce bioactive compounds. Furthermore, the re-isolation of previously known 
compounds is still considered a worthwhile pursuit particularly for finding new pharmacological uses 
such as anti-infectives. The emergence of antibiotic resistance and the alarming death rate caused by 
infectious diseases necessitates the need for re-evaluating the current multitude of compounds that 
have been discovered over the past years. 
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